A Nasdaq float is scrapped, but for Poseida that’s great news
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Kiadis moves to reduce reliance on its in-house lead
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
AACR 2019 – Baylor sets the benchmark for Bellicum
A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.
Smith & Nephew buys Osiris and insists it has appetite for more
The UK ortho and woundcare group might yet pounce on Nuvasive.
Off-the-shelf approaches keep cell therapy investors keen
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
Caladrius refuses to give up on Tregs for diabetes
After a trial failure last week, Caladrius Biosciences has not abandoned hope for its T regulatory cell therapy in type 1 diabetes, but funding might become a problem.
Reneuron eyes a partner with new stem cell data
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.
Novartis and Gilead’s multiple myeloma CARs diverge
As Gilead bows out of BCMA, Novartis pins its hopes on a BCMA/CD19 combo.
Years of dreams about CARs turn into reality for Atara
The company’s nascent CAR-T portfolio includes technology licensed from one of the field’s most prominent pioneers.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.